|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.9807 USD | -0.96% |
|
+2.13% | +78.31% |
| 06-13 | Xilio Therapeutics, Inc. Announces Board Appointments | CI |
| 05-14 | Xilio Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Akriveia Therapeutics, LLC announced that it will receive $22,500,000 in a round of funding on January 23, 2018. The company will issue convertible preferred stock in the transaction. The company intends the transaction to last more than one year.
The company will issue securities pursuant to the exemption provided under Regulation D.
| 1st Jan change | Capi. | |
|---|---|---|
| +78.31% | 36.2M | |
| +24.74% | 47.54B | |
| -0.47% | 41.96B | |
| +46.11% | 41.55B | |
| +25.40% | 30.36B | |
| +17.96% | 27.61B | |
| -4.47% | 28.7B | |
| +50.73% | 14.7B | |
| +42.56% | 13.51B | |
| +1.46% | 12.34B |
XILIO THERAPEUTICS, INC. 
